A unified definition of clinical anthracycline resistance breast cancer

Por Pivot, X, Asmar, L, Buzdar, A U, Valero, V, Hortobagyi, G
Publicado em 2000

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

Por Pivot, X., Marmé, F., Koenigsberg, R., Guo, M., Berrak, E., Wolfer, A.
Publicado no Ann Oncol (2016)

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer

Por Royer, B, Yin, W, Pegram, M, Ibrahim, N, Villanueva, C, Mir, D, Erlandsson, F, Pivot, X
Publicado em 2010

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

Por Llombart-Cussac, A., Pivot, X., Contesso, G., Rhor-Alvarado, A., Delord, J. P., Spielmann, M., Türsz, T., Le Cesne, A.
Publicado em 1998

Breast cancer screening in France: results of the EDIFICE survey

Por Pivot, X, Rixe, O, Morere, JF, Coscas, Y, Cals, L, Namer, M, Serin, D, Dolbeault, S, Eisinger, F, Roussel, C, Blay, JY
Publicado em 2008

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Por Miles, D W, de Haas, S L, Dirix, L Y, Romieu, G, Chan, A, Pivot, X, Tomczak, P, Provencher, L, Cortés, J, Delmar, P R, Scherer, S J
Publicado em 2013

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma

Por Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, Kleinclauss F, Pivot X, Limat S, Thiery-Vuillemin A
Publicado em 2014-02-01

A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head an...

Por Etienne, M C, Pivot, X, Formento, J L, Bensadoun, R J, Formento, P, Dassonville, O, Francoual, M, Poissonnet, G, Fontana, X, Schneider, M, Demard, F, Milano, G
Publicado em 1999

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

Por Pivot, X, Raymond, E, Laguerre, B, Degardin, M, Cals, L, Armand, J P, Lefebvre, J L, Gedouin, D, Ripoche, V, Kayitalire, L, Niyikiza, C, Johnson, R, Latz, J, Schneider, M
Publicado em 2001

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado em 2007

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado em 2008

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study

Por Royer, B, Kalbacher, E, Onteniente, S, Jullien, V, Montange, D, Piedoux, S, Thiery-Vuillemin, A, Delroeux, D, Pili-Floury, S, Guardiola, E, Combe, M, Muret, P, Nerich, V, Heyd, B, Chauffert, B, Kantelip, J-P, Pivot, X
Publicado em 2012

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

Por Adotevi, O., Godet, Y., Galaine, J., Lakkis, Z., Idirene, I., Certoux, J. M., Jary, M., Loyon, R., Laheurte, C., Kim, S., Dormoy, A., Pouthier, F., Barisien, C., Fein, F., Tiberghien, P., Pivot, X., Valmary-Degano, S., Ferrand, C., Morel, P., Delabrousse, E., Borg, C.
Publicado no Oncoimmunology (2018)